Ignace Vergote Selected Research

Biomarkers (Surrogate Marker)

4/2024	ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
10/2023	Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
6/2023	Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.
1/2023	Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
1/2023	Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
11/2022	A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
3/2022	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.
1/2022	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.
1/2022	Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
11/2021	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ignace Vergote Research Topics

Disease

199	Ovarian Neoplasms (Ovarian Cancer) 05/2024 - 01/2003
179	Neoplasms (Cancer) 05/2024 - 01/2003
48	Carcinoma (Carcinomatosis) 04/2024 - 01/2002
41	Ovarian Epithelial Carcinoma 05/2024 - 02/2003
38	Endometrial Neoplasms (Endometrial Cancer) 04/2024 - 03/2002
30	Uterine Cervical Neoplasms (Cancer of the Cervix) 03/2024 - 01/2002
29	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2003
19	Disease Progression 12/2023 - 07/2003
15	Ascites 03/2022 - 12/2005
12	Neutropenia 01/2023 - 05/2003
10	Nausea 03/2024 - 05/2003
10	Neoplasm Metastasis (Metastasis) 03/2023 - 01/2002
8	Vomiting 03/2024 - 04/2012
8	Fatigue 11/2022 - 02/2012
8	Residual Neoplasm 01/2022 - 02/2003
6	Hypertension (High Blood Pressure) 01/2023 - 05/2014
6	Thrombocytopenia (Thrombopenia) 01/2023 - 10/2014
6	Anemia 11/2022 - 04/2012
5	Vulvar Neoplasms (Vulvar Cancer) 11/2021 - 09/2008
5	Fallopian Tube Neoplasms 01/2021 - 04/2016
5	Carcinogenesis 03/2016 - 12/2008
4	Peritoneal Neoplasms 03/2023 - 01/2014
4	Carcinosarcoma 01/2023 - 11/2003
4	Proteinuria 01/2022 - 05/2014
4	Diarrhea 01/2019 - 10/2014
4	Endometrioid Carcinoma 10/2015 - 12/2008
3	Genomic Instability 06/2023 - 01/2023
3	Pain (Aches) 10/2022 - 12/2005
3	Chromosomal Instability (Chromosome Stability) 04/2022 - 01/2016
3	Adenocarcinoma 01/2021 - 03/2007

Drug/Important Bio-Agent (IBA)

101	PlatinumIBA 05/2024 - 01/2003
41	Paclitaxel (Taxol)FDA LinkGeneric 03/2024 - 03/2003
40	Carboplatin (JM8)FDA LinkGeneric 04/2024 - 10/2006
35	Biomarkers (Surrogate Marker)IBA 04/2024 - 02/2003
25	olaparibIBA 04/2024 - 02/2012
24	Bevacizumab (Avastin)FDA Link 04/2024 - 05/2014
18	Proteins (Proteins, Gene)FDA Link 04/2024 - 04/2009
14	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2024 - 02/2012
14	liposomal doxorubicin (Doxil)FDA Link 01/2023 - 07/2010
13	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 02/2003
13	Estrogen ReceptorsIBA 01/2019 - 02/2003
13	Hormones (Hormone)IBA 06/2017 - 02/2003
12	DNA (Deoxyribonucleic Acid)IBA 05/2024 - 05/2014
12	Messenger RNA (mRNA)IBA 05/2024 - 12/2006
10	Immunoconjugates (Immunoconjugate)IBA 03/2024 - 07/2018
9	Estrogens (Estrogen)FDA Link 01/2018 - 06/2004
8	taxaneIBA 04/2024 - 07/2010
7	ErbB Receptors (EGF Receptor)IBA 05/2024 - 06/2007
7	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 01/2005
7	1-dodecylpyridoxal (PLD)IBA 01/2022 - 07/2010
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2019 - 02/2012
7	Aromatase InhibitorsIBA 02/2014 - 05/2004
6	Topotecan (Hycamtin)FDA LinkGeneric 03/2024 - 05/2003
6	mirvetuximab soravtansineIBA 03/2024 - 01/2018
6	ParaffinIBA 06/2023 - 12/2008
6	VaccinesIBA 01/2022 - 09/2010
6	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2015
6	Tamoxifen FDA LinkGeneric 01/2018 - 11/2003
5	niraparibIBA 03/2024 - 12/2016
5	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2021
5	pembrolizumabIBA 11/2023 - 01/2022
5	tisotumab vedotinIBA 08/2023 - 01/2020
5	Gemcitabine FDA Link 06/2021 - 03/2003
5	trebananibIBA 01/2019 - 07/2014
5	Folic Acid (Vitamin M)FDA LinkGeneric 07/2018 - 05/2014
5	Fulvestrant (Faslodex)FDA Link 05/2008 - 07/2003
4	AntigensIBA 12/2023 - 09/2011
4	Thromboplastin (Tissue Factor)IBA 08/2023 - 01/2020
4	Tyrosine Kinase InhibitorsIBA 01/2023 - 06/2007
4	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2021 - 06/2016
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2020 - 05/2014
4	Interleukin-10 (Interleukin 10)IBA 11/2019 - 04/2014
4	MicroRNAs (MicroRNA)IBA 01/2016 - 06/2011
4	thiaclopridIBA 02/2015 - 08/2011
4	Transcription Factors (Transcription Factor)IBA 01/2015 - 12/2008
4	Anastrozole (Arimidex)FDA LinkGeneric 02/2011 - 07/2003
3	Circulating Tumor DNAIBA 05/2024 - 02/2015
3	selinexorIBA 04/2024 - 12/2023
3	Folate Receptor 1IBA 03/2024 - 10/2018
3	Tumor Biomarkers (Tumor Markers)IBA 05/2023 - 06/2007
3	Taxoids (Taxanes)IBA 01/2023 - 08/2011
3	lenvatinibIBA 01/2023 - 01/2020
3	CyclinsIBA 01/2023 - 01/2014
3	CytokinesIBA 11/2021 - 01/2018
3	Adenosine Diphosphate (ADP)IBA 12/2019 - 04/2012

Therapy/Procedure

106	Drug Therapy (Chemotherapy) 04/2024 - 01/2003
84	Therapeutics 05/2024 - 05/2003
27	Neoadjuvant Therapy 11/2023 - 11/2005
18	Lymph Node Excision (Lymph Node Dissection) 11/2021 - 01/2002
17	Immunotherapy 04/2024 - 09/2010
13	Adjuvant Chemotherapy 11/2021 - 01/2003
11	Cytoreduction Surgical Procedures 12/2021 - 02/2011
10	Radiotherapy 11/2021 - 01/2002
10	Hysterectomy 01/2021 - 03/2007
6	Aftercare (After-Treatment) 03/2024 - 03/2003
6	Hyperthermic Intraperitoneal Chemotherapy 12/2023 - 01/2018
5	Palliative Care (Palliative Therapy) 03/2023 - 03/2003
4	Investigational Therapies (Experimental Therapy) 01/2023 - 01/2017
4	Salpingo-oophorectomy 01/2020 - 01/2008
3	Minimally Invasive Surgical Procedures 11/2021 - 01/2016